Recent evidence suggests multiple drug therapy is superior to single agents. The study
compares the incidence of nausea, vomiting, need for rescue medication, prolonged PACU time,
and unplanned hospital admission in patients with high risk for PONV treated with oral
aprepitant with or without transdermal scopolamine preoperatively.
Postoperative nausea and vomiting (PONV) is a serious problem complicating surgery. PONV
has an overall incidence of 30% and a 70% incidence in high-risk patients. PONV yields
unplanned hospital admission, pulmonary aspiration, esophageal rupture, electrolyte
abnormalities, dehydration, and delayed discharge from the postanesthesia care unit (PACU).
Additional use of resources costs the health care industry hundreds of millions of dollars
annually. Patient satisfaction is greatly improved when PONV is prevented.4 PONV etiology is
multifactorial and the treatment is multimodal.
- Patient must be between 18 and 65 years of age.
- Patient's ASA class must be between 1 and 3.
- If patient is currently on oral contraceptive to prevent pregnancy, she must be
willing to use a back up form of birth control for one month post study.
- Patient must have 1 FACTOR to qualify
- Female Sex
- History of PONV
- Motion Sickness
- Intended Use of Post Operative Opioids
- Patients with a history of vomiting due to middle ear infection, nervous system
disorder, or any other condition.
- The surgical procedure is less than 1 hour.
- The patient is pregnant or breast feeding.
- The patient has taken antiemetic medication in previous 24 hours.
- Patients with narrow-angle glaucoma.
- Allergy to belladonna alkaloids.
- Hypersensitivity to barbiturates.
- Patient taking any of the following medications:
- Tricyclic Antidepressants
- Aluminum and Magnesium Trisilicate-containing Antacids
- Male patients with prostate hypertrophy.
- Patients with severe hepatic disease.
- Patients on Chemotherapy and taking Aprepitant.
- Patients with fever.
- Patients with sepsis.